These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34380696)

  • 1. Critical Role for Hepatocyte-Specific eNOS in NAFLD and NASH.
    Cunningham RP; Moore MP; Dashek RJ; Meers GM; Takahashi T; Sheldon RD; Wheeler AA; Diaz-Arias A; Ibdah JA; Parks EJ; Thyfault JP; Rector RS
    Diabetes; 2021 Nov; 70(11):2476-2491. PubMed ID: 34380696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. eNOS deletion impairs mitochondrial quality control and exacerbates Western diet-induced NASH.
    Sheldon RD; Meers GM; Morris EM; Linden MA; Cunningham RP; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E605-E616. PubMed ID: 31361543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis.
    Jin K; Shi Y; Zhang H; Zhangyuan G; Wang F; Li S; Chen C; Zhang J; Wang H; Zhang W; Sun B
    J Hepatol; 2023 Aug; 79(2):403-416. PubMed ID: 37040844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
    Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
    Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution.
    Nozaki Y; Fujita K; Wada K; Yoneda M; Shinohara Y; Imajo K; Ogawa Y; Kessoku T; Nakamuta M; Saito S; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
    BMC Gastroenterol; 2015 Dec; 15():177. PubMed ID: 26678309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte-specific eNOS deletion impairs exercise-induced adaptations in hepatic mitochondrial function and autophagy.
    Cunningham RP; Moore MP; Dashek RJ; Meers GM; Jepkemoi V; Takahashi T; Vieira-Potter VJ; Kanaley JA; Booth FW; Rector RS
    Obesity (Silver Spring); 2022 May; 30(5):1066-1078. PubMed ID: 35357089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult-Onset Hepatocyte GH Resistance Promotes NASH in Male Mice, Without Severe Systemic Metabolic Dysfunction.
    Cordoba-Chacon J; Sarmento-Cabral A; Del Rio-Moreno M; Diaz-Ruiz A; Subbaiah PV; Kineman RD
    Endocrinology; 2018 Nov; 159(11):3761-3774. PubMed ID: 30295789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function.
    Wolff G; Sakurai M; Mhamane A; Troullinaki M; Maida A; Deligiannis IK; Yin K; Weber P; Morgenstern J; Wieder A; Kwon Y; Sekar R; Zeigerer A; Roden M; Blüher M; Volk N; Poth T; Hackert T; Wiedmann L; De Angelis Rigotti F; Rodriguez-Vita J; Fischer A; Mukthavaram R; Limphong P; Tachikawa K; Karmali P; Payne J; Chivukula P; Ekim-Üstünel B; Martinez-Jimenez CP; Szendrödi J; Nawroth P; Herzig S
    Mol Metab; 2022 Jun; 60():101487. PubMed ID: 35378329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver.
    Lee SM; Pusec CM; Norris GH; De Jesus A; Diaz-Ruiz A; Muratalla J; Sarmento-Cabral A; Guzman G; Layden BT; Cordoba-Chacon J
    Cell Mol Gastroenterol Hepatol; 2021; 11(5):1291-1311. PubMed ID: 33444819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
    Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
    Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression.
    Bruinstroop E; Zhou J; Tripathi M; Yau WW; Boelen A; Singh BK; Yen PM
    Mol Metab; 2021 Nov; 53():101266. PubMed ID: 34098145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective and Detrimental Roles of p38α Mitogen-Activated Protein Kinase in Different Stages of Nonalcoholic Fatty Liver Disease.
    Hwang S; Wang X; Rodrigues RM; Ma J; He Y; Seo W; Park SH; Kim SJ; Feng D; Gao B
    Hepatology; 2020 Sep; 72(3):873-891. PubMed ID: 32463484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.
    Latif MU; Schmidt GE; Mercan S; Rahman R; Gibhardt CS; Stejerean-Todoran I; Reutlinger K; Hessmann E; Singh SK; Moeed A; Rehman A; Butt UJ; Bohnenberger H; Stroebel P; Bremer SC; Neesse A; Bogeski I; Ellenrieder V
    Gut; 2022 Dec; 71(12):2561-2573. PubMed ID: 35365570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.